크레아티닌 측정 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the creatinine measurement market size is projected to be USD 0.79 billion in 2025, USD 0.86 billion in 2026, and reach USD 1.29 billion by 2031, growing at a CAGR of 8.5% from 2026 to 2031.

This report is Segmented by Product Type (Reagents & Kits, Clinical Chemistry Analyzers, and More), Test Method (Jaffe, Enzymatic), Sample Type (Blood Serum/Plasma, Whole Blood, Urine), Testing Setting (Central Laboratory, Point-Of-Care), End User (Hospitals & Clinics, Diagnostic Laboratories, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Creatinine Measurement Market Trends and Insights

Rising CKD Prevalence And Screening Intensity

CKD affects more than 35 million adults in the United States, while China counts 132 million citizens with reduced kidney function, yet only 12.5% of Chinese patients are aware of their condition. National health agencies now embed creatinine and eGFR testing into primary-care protocols, and China's 2024 community-health guidelines direct mass screening with portable analyzers. Japan's dialysis registry reported 349,700 patients in 2023, each undergoing monthly creatinine checks to fine-tune treatment adequacy. In the United States, Medicare's Merit-based Incentive Payment System rewards physicians who document albumin-to-creatinine ratio results, lifting outpatient test volumes. Together, these programs funnel high-frequency samples into both laboratories and point-of-care channels, sustaining the creatinine measurement market.

Adoption Of Point-Of-Care Creatinine/eGFR Testing In Radiology And Critical Care

Radiology and intensive-care teams are relocating creatinine testing from central labs to bedside devices, shrinking turnaround from hours to minutes. Abbott's i-STAT cartridge delivers results in two minutes from 65 µL of whole blood and demonstrated an R2 = 0.99 correlation with core-lab assays in a 2024 Queensland ICU study. The U.K. National Institute for Health and Care Excellence endorses point-of-care creatinine devices for pre-contrast CT workflows, accelerating adoption in emergency imaging. Nova Biomedical's StatSensor generates eGFR on-device in 30 seconds from a fingerstick, expanding use in community pharmacies and low-resource HIV clinics in Tanzania. These capabilities reinforce the value proposition of the creatinine measurement market where rapid decision making prevents contrast-induced nephropathy and accelerates patient throughput.

Jaffe Method Interferences And Between-Method Variability

Positive interference from bilirubin and hemoglobin can inflate Jaffe results by up to 20%, while antibiotics may suppress readings, risking medication errors. A 2025 Annals of Laboratory Medicine review showed 4.6% LOINC mapping errors when aggregating multi-site results, underscoring how unharmonized methods can compromise longitudinal data. Siemens' Atellica CH Creatinine 3 assay introduces rate blanking and a 0.3 mg/dL bias correction but still faces cost-driven inertia compared with enzymatic reagents. These issues temper the otherwise robust outlook for the creatinine measurement market.

Other drivers and restraints analyzed in the detailed report include:

1. Shift From Jaffe To IDMS-Traceable Enzymatic Assays
2. Expansion Of ACR Screening In Diabetes And Hypertension Programs
3. Substitution Risk From Alternative Renal Biomarkers

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Reagents and kits contributed 42.55% of 2025 revenue, establishing the largest slice of the creatinine measurement market size as laboratories lock into multi-year consumable contracts. Point-of-care meters and handhelds are forecast to rise 9.25% annually to 2031, propelled by imaging-suite protocols that demand under-two-minute turnaround. Clinical chemistry analyzers like Beckman Coulter's DxC 500i run 800 tests per hour, safeguarding core-lab dominance, while Roche's cobas c 703 doubles throughput to 2,000 tests per hour, underpinning reagent demand.

Calibrators and controls, though smaller in sales, secure assay traceability to NIST's SRM 967b and satisfy CLIA quality mandates. Roche's EUR 600 million facility under construction in Penzberg will automate antibody and enzyme production, reinforcing supply lines for global customers. Siemens promises 98% uptime on e-connected Atellica systems, sharpening service differentiation. In emerging economies, generic reagents from Asia introduce price pressure, yet bundled service contracts and uptime guarantees keep multinationals competitive within the creatinine measurement market.

Jaffe chemistry controlled 54.53% of the creatinine measurement market share in 2025 thanks to entrenched analyzer fleets and a 20-30% cost edge. Enzymatic assays are advancing at a 9.05% CAGR to 2031 as laboratories seek tighter alignment with IDMS standards and lower interference. The creatinine measurement industry also benefits from regulatory nudges; the FDA's dosing guidance effectively favors enzymatic methods for drug-label compliance.

Vendors pursue a dual-track strategy. Roche and Beckman Coulter list both Jaffe and enzymatic reagents, allowing budget-constrained labs to transition gradually. Siemens' modified Jaffe assay extends the life of legacy systems while offering rate blanking to cut bilirubin interference. As multi-center research networks demand harmonized data, enzymatic uptake will continue to erode Jaffe dominance, reinforcing momentum in the creatinine measurement market.

Geography Analysis

North America held 41.15% of 2025 revenue, propelled by 571,000 dialysis patients, Medicare incentives for ACR testing, and FDA guidance that prioritizes eGFR reporting. Canada invests in point-of-care devices to cut emergency wait times, while Mexico's expanding private diagnostic sector taps mid-range analyzers.

Europe's universal health systems and IVDR regulations guide method standardization. UK NEQAS data affirm enzymatic assays meet KDIGO bias targets better than Jaffe methods, shaping National Health Service procurement. Roche's Penzberg facility will bolster continental reagent supply chains by 2028. Yet ESUR risk-stratification protocols may temper radiology-point-of-care volumes.

Asia-Pacific is forecast to post a 9.51% CAGR, the fastest among regions. China's 132 million-patient CKD burden, India's expanding lab chains, and Japan's world-leading dialysis prevalence fuel demand. Community-health screening directives and tiered care models favor portable analyzers. South Korea and Australia, though smaller, feature rapid AI adoption and regulatory clarity, fostering early uptake of IDMS-aligned assays. Middle East, Africa, and South America contribute modest volumes but adopt refurbished analyzers and lower-priced reagents, while Gulf Cooperation Council countries invest in premium hospital infrastructure.

1. Abbott Laboratories
2. Beckman Coulter (Danaher)
3. Beijing Leadman Biochemistry
4. Dialab GmbH
5. DiaSys Diagnostic Systems
6. Diazyme Laboratories
7. Elitech Group
8. FUJIFILM (Wako Diagnostics)
9. HemoCue
10. Kanto Chemical
11. Mindray
12. Nova Biomedical
13. Pointe Scientific (HORIBA)
14. QuidelOrtho
15. Radiometer
16. Randox Laboratories
17. Roche
18. Sekisui Diagnostics
19. Sentinel Diagnostics
20. Mindray
21. Siemens Healthineers
22. Teco Diagnostics
23. Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising CKD prevalence and screening intensity
  • 4.2.2 Adoption of point-of-care creatinine/eGFR testing in radiology and critical care
  • 4.2.3 Shift from Jaffe to IDMS-traceable enzymatic assays
  • 4.2.4 Expansion of ACR (albumin-to-creatinine ratio) screening in diabetes and hypertension programs
  • 4.2.5 Implementation of race-free CKD-EPI eGFR reporting in labs
• 4.3 Market Restraints
  • 4.3.1 Jaffe method interferences and between-method variability
  • 4.3.2 Reagent price pressure and commoditization in clinical chemistry
  • 4.3.3 Substitution risk from alternative renal biomarkers in specific pathways
  • 4.3.4 Guideline shifts that reduce routine pre-contrast testing in low-risk populations
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Reagents & Kits
  • 5.1.2 Clinical Chemistry Analyzers
  • 5.1.3 POC Devices - Meters/Handhelds
  • 5.1.4 POC Cartridges/Strips
  • 5.1.5 Calibrators & Controls
• 5.2 By Test Method
  • 5.2.1 Jaffe (kinetic/compensated)
  • 5.2.2 Enzymatic (IDMS-traceable)
• 5.3 By Sample Type
  • 5.3.1 Blood (Serum/Plasma)
  • 5.3.2 Whole Blood (POC)
  • 5.3.3 Urine
• 5.4 By Testing Setting
  • 5.4.1 Central Laboratory
  • 5.4.2 Point-of-Care
• 5.5 By End User
  • 5.5.1 Hospitals & Clinics
  • 5.5.2 Diagnostic Laboratories
  • 5.5.3 Primary Care/Outpatient
  • 5.5.4 Dialysis Centers
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abbott
  • 6.3.2 Beckman Coulter (Danaher)
  • 6.3.3 Beijing Leadman Biochemistry
  • 6.3.4 Dialab GmbH
  • 6.3.5 DiaSys Diagnostic Systems
  • 6.3.6 Diazyme Laboratories
  • 6.3.7 ELITechGroup
  • 6.3.8 FUJIFILM (Wako Diagnostics)
  • 6.3.9 HemoCue
  • 6.3.10 Kanto Chemical
  • 6.3.11 Mindray
  • 6.3.12 Nova Biomedical
  • 6.3.13 Pointe Scientific (HORIBA)
  • 6.3.14 QuidelOrtho
  • 6.3.15 Radiometer
  • 6.3.16 Randox Laboratories
  • 6.3.17 Roche Diagnostics
  • 6.3.18 Sekisui Diagnostics
  • 6.3.19 Sentinel Diagnostics
  • 6.3.20 Shenzhen Mindray Bio-Medical Electronics
  • 6.3.21 Siemens Healthineers
  • 6.3.22 Teco Diagnostics
  • 6.3.23 Thermo Fisher Scientific

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment